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Background & Aims:  Folate is an essential nutrient required for many different functions in 29 
the body. It is particularly important for DNA synthesis, immune functions and during 30 
pregnancy. Folate supplements are commonly prescribed by health professionals for a 31 
number of different conditions, however, the absorption of the different derivatives remains 32 
unclear. The aim of this review was to assess the bioavailability of various forms of folate 33 
supplements in  healthy populations and animal models. 34 
 35 
Methods: A systematic literature review was conducted of original research which assessed 36 
the bioavailability of different oral forms of folate in healthy adults or animal models. The 37 
following databases were searched: PubMed (US National Library of Medicine), ProQuest 38 
Medical Collection (ProQuest) and ScienceDirect (Elsevier) up to 30th March 2017. The 39 
inclusion criteria consisted of both animal and human research, no disease state or condition 40 
and assessed levels after an intervention of a folate derivative. 41 
 42 
Results: A total of 23 studies out of 5226 met the full inclusion criteria. Of these, four were 43 
animal studies and 19 were human studies. There was variation in supplement forms used 44 
with the most commonly tested being folic acid followed by 5-MTHF. Dosages ranged from 45 
25µg up to 200mg. Only three studies found a statistically significant difference in folate 46 
bioavailability when evaluating different supplement forms. These studies found 5-MTHF to 47 
be more effective at increasing folate levels in participants.   48 
   49 
Conclusions:  This review has found a number of methodological limitations and conflicting 50 
results. Only three out of the 23 studies assessed found a statistically significant difference 51 
between different supplemental forms of folate. Quality absorption studies assessing the 52 
bioavailability of oral folate supplements is crucial if clinicians are to make effective evidence 53 
based recommendations. More research is required for greater clarification regarding the 54 
bioavailability of these supplements. 55 
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INTRODUCTION 59 
 60 
There are several different forms of oral folate supplements available to clinicians and the 61 
general public. Numerous studies have assessed the efficacy of folate supplements for 62 
different conditions and disease states 1-3, however, relatively little literature has been 63 
published on the absorption and bioavailability of different folate supplements. To date, there 64 
has been conflicting information generated on the internet and by supplementation companies 65 
which has led to uncertainty regarding the most effective oral folate supplement for healthy 66 
individuals.. Folate is an essential nutrient required for many different functions in the body 67 
and is particularly important for DNA synthesis, immune functions and during pregnancy. This 68 
paper will review the current literature focusing on the bioavailability of various oral forms of 69 





Folate is the generic term for a B group vitamin which functions as a carbon donor in the 75 
synthesis of amino acids, purines and pyrimidine bases required for DNA synthesis 4.  It also 76 
functions as methyl donor in the production of methylcobalamin and methionine 4. It is found 77 
in a wide range of foods including whole grains, legumes and green leafy vegetables 5. Folate 78 
supplements have shown to be effective for a number of conditions  including Alzheimer's 79 
disease 6, sleep problems 7 and depression 8. It is often prescribed alongside medications, 80 
such as methotrexate, to reduce unwanted and harmful side effects of the medication 9.  81 
 82 
Under the Australian New Zealand Food Standards Code, Australian millers have been 83 
required to add folic acid to wheat flour used for bread making since September 2009.  The 84 
flour has to contain 2-3mg of folic acid per kg. This equates to three slices of bread providing 85 
approximately half of the recommended daily intake of folate 10. However, not all countries 86 
have implemented this fortification 11. To assess the efficacy of this intervention, a 87 
retrospective analysis of serum and RBC folate samples collected between 2007 and 2010 88 
were analysed. A total of 20 592 blood samples were evaluated and a 31% increase in mean 89 
serum folate and a 22% increase in mean RBC folate level was observed highlighting the 90 
success of the fortification policy in improving folate status 10. Given the importance of this 91 
policy, understanding if any differences exist between supplemental forms of folate is crucial. 92 
Especially when considering other influencing factors such as enzyme activity.  93 
 94 
A percentage of the population are unable to properly metabolise folate because they have 95 
defects with the methylenetetrahydrofolate reductase (MTHFR) enzyme. MTHFR is the rate-96 
limiting enzyme in the methylation cycle, and it is encoded by the MTHFR gene 12. This 97 
enzyme is responsible for converting 5, 10 methylene tetrahydrofolate into 5 – methyl 98 
tetrahydrofolate by adding methyl groups to make folate bioavailable to the body 12.  99 
Individuals who have impaired MTHFR activity have a reduced ability to convert 5,10-100 
Methylenetetrahydrofolate into 5-methyltetrahydrofolate 13. Due to this reduced activity they 101 
may have difficulty processing folic acid from supplements and fortified foods. Other 102 
independent factors to consider include intestinal absorption and transport of folate. The 103 
reduced folate carrier (RFC) and the proton-coupled folate transporter (PCFT) are involved in 104 
mediating folate transport across the epithelia and into systemic tissues contribute to folate 105 
homeostasis 14. 106 
 107 
There are several variations when it comes to MTHFR mutations depending on which genes 108 
are passed on from each parent. Currently 34 mutations have been identified with the MTHFR 109 
gene which are associated with enzymatic deficiency 12. A 2003 study which assessed the 110 
MTHFR status of 7000 newborns over 16 areas worldwide found that between 60–70% of 111 
individuals will have at least one of these polymorphisms 15. 112 
 113 
The folate vitamers found in whole foods typically occur as reduced methyl- and formyl-114 
polyglutamate forms 4. This is different from the structure of synthetic forms used in 115 
supplements and food fortification. Due to the chemical differences in structure, there is a 116 
difference in bioavailability.  In 1998 The Institute of Medicine introduced the use of dietary 117 
folate equivalents in order to adjust for the variations in bioavailability of food folate and 118 
synthetic forms 16. Several different forms are used in dietary supplements. Folic acid, folinic 119 
acid and 5-methyltetrahydrofolate are the most commonly available oral vitamin supplements 120 
available world-wide. However, there is limited research assessing their bioavailability. This 121 
review aims to critically apprise the current evidence on oral folate bioavailability and discuss 122 





A protocol was developed according to the Preferred Reporting Items For Systematic Reviews 128 
And Meta-Analysis Protocols (PRISMA-P) 2015 statement 17. 129 
 130 
Search Strategies and Inclusion Criteria  131 
A literature search was conducted in the following databases: PubMed (US National Library 132 
of Medicine), ProQuest Medical Collection (ProQuest) and ScienceDirect (Elsevier). All 133 
authors contributed to the development of search terms and inclusion/exclusion criteria. 134 
Search terms were divided in two groups and combined within the search. Group 1: folate OR 135 
folic acid OR folinic acid OR 5 MTHF OR 5-methyltetrahydrofolate OR Tetrahydrofolate. Group 136 
2: absorption OR bioavailability OR pharmacokinetics OR oral OR pharmacodynamics. 137 
Original research which assessed the bioavailability of different oral forms of folate in healthy 138 
adults or animal models were included in the review published up to the 30th March 2017  139 
 140 
 141 
Study Selection and Data Extraction 142 
The initial search identified 5226 papers. After removal of 128 duplicates, articles were 143 
screened by title and by abstract. The remaining articles were then screened by full text 144 
resulting in 23 articles which met the full inclusion criteria to be assessed in this review. 145 
Screening was performed by JB and citations were stored and filed in EndNote X7. Articles 146 
were excluded from the review for the following reasons; articles were not in English; articles 147 
were not related to the topic; not original research; studies which examined folate in disease 148 
states; trials assessing folate from whole foods or fortified products; studies testing efficacy of 149 
folate supplements in conjunction with medications or studies looking at correcting a folate 150 
deficiency. The article selection process is outlined in figure 1.  151 
 152 
INSERT FIGURE #1 153 
 154 
Assessment of Risk of Bias and Data Summary Table: 155 
Each paper was critically appraised for methodological consistency using the Joanna Briggs 156 
Institute Critical Appraisal tool for Systematic Reviews. The Checklist for Quasi-Experimental 157 
Studies was used for thirteen of the studies and the Checklist for Randomised Control Trials 158 
was used for six of the studies 18. The critical appraisal tools assessed the 19 human studies 159 
included in this literature review. Overall the appraisal found reliable methodology and no 160 
papers were excluded from the review. The results for quasi-experimental studies are 161 
displayed in Table 1 and the results for randomised control trials (RCTs) are displayed in Table 162 
2. During this process data was extracted from the final articles and summarised in Tables 3 163 
and 4. 164 
 165 
INSERT TABLE #1 166 
INSERT TABLE #2 167 
INSERT TABLE #3 168 
INSERT TABLE #4 169 
 170 
LIMITATIONS OF THIS REVIEW 171 
 172 
This review has several limitations of its own which need to be considered. Only articles 173 
available in English were included, which may have resulted in important research being 174 
omitted from the review. Another consideration is publication bias. Only published trials 175 
available on the pre-selected data-bases were available to be reviewed which may have 176 
skewed the findings. All in vitro, animal and human studies which met the inclusion criteria 177 
were assessed in this review. Differences exist between clinical and animal studies and 178 
supplementation preparations vary accordingly. This should be considered when interpreting 179 
the results from this review.  180 
 181 
 182 
RESULTS  183 
 184 
A total of 23 studies out of the original 5226 papers identified fit the full inclusion criteria and 185 
were appraised in this review. All studies provided quantitative data with 4 trials 19-22 using 186 
animal models and 19 studies 23-41 conducting human trials.  187 
 188 
The studies varied in length from 8 hours to 24 weeks. Twelve studies 19,20,22,24-26,30,33,37,38,40,41 189 
administered the intervention as an individual dose and measured outcomes at various 190 
intervals over the next 8-24 hours. Seven 23-26,37,40,41 of those studies included a washout period 191 
of at least 1 week between the first intervention and the second. Three studies 25,26,33 also 192 
included a saturation period where participants were pre-dosed with folate prior to beginning 193 
the trial. Two studies 31,32 included a run-in period with a placebo for 5 weeks to get participants 194 
accustomed to taking supplements.  195 
 196 
The main outcome measure utilised by 17 of the human trials 23,24,27-41 included plasma or 197 
serum folate. Two studies 25,26 measured 24 hour urine. Five studies 27,31,32,35,41 measured RBC 198 
folate and five trials 29,31,32,34,39 also included homocysteine as an outcome measure. A 199 
summary is provided in Table 5 below. All studies measured key outcomes at baseline level. 200 
The animal studies also measured tissue samples at the conclusion of the trials.  201 
 202 
INSERT TABLE #5 203 
 204 
In the human studies, five studies 23,25,26,33,37 tested only males and four 27,35,38,40 tested only 205 
females. Three studies 31,32,34 failed to clearly specify the gender of their participants and the 206 
remaining seven studies 24,28-30,36,39,41 included both sexes.  207 
 208 
Four studies 31,32,34,39 were conducted on older adults (>50yrs) with one study 34 comparing an 209 
intervention in a group of older adults to a group of younger adults. One study 38 was 210 
conducted on healthy pregnant women with no signs of pre-existing disease conditions.  211 
 212 
The number of participants included in the 19 human trials varied greatly with the average 213 
number of participants being 42. The boxplot in Figure 2 displays the minimum (5), Q1 (9), 214 
median (16), Q3 (35) and the range (175) of participants. 215 
 216 
INSERT FIGURE #2 217 
  218 
A number of different themes were present throughout the studies. Three trials 23,27,35 tested 219 
varying different dosages of folate to see the effect on outcome measures. Twelve studies 220 
19,21,22,26,28,29,31-36 compared two or more different forms of folate against each other. One study 221 
tested a soft gel capsule vs a tablet 40 and another looked at a powdered formula verses a 222 
tablet 38. Two studies 29,31 included individuals with MTHFR gene mutations. 223 
 224 
There was also great variation in the forms of folate supplements used. The most frequently 225 
tested supplement was folic acid with 15 trials 19-22,25-27,29,30,33-35,38-40 using this form. The second 226 
most common was (6S)-5-methyltetrahydrofolate with 8 trials 21,22,26,29,33-35,37 assessing its 227 
efficacy. Table 6 highlights the different supplements used.  228 
 229 
INSERT TABLE #6 230 
 231 
The dosages used in the human trials varied greatly from only 25µg up to 200mg. Of the twelve 232 
studies 19,21,22,26,28,29,31-36 which compared two or more different forms of folate, nine studies 233 
19,26,28,29,31-34,36 showed no significant differences between the groups and three studies 21,22,35 234 




  239 
Health practitioners may recommend folate supplements for a number of different conditions. 240 
Currently, the oral folate supplements available include folic acid, folinic acid and 5-MTHF. 241 
The most bioavailable form in healthy populations remains unclear. Identifying the most 242 
effective oral form of folate will facilitate advancements in this field and may assist in improving 243 
patient health and outcomes.  244 
 245 
This is the first review to explore the bioavailability of different oral forms of folate 246 
supplementation in a healthy population. The review highlighted that only twelve studies 247 
19,21,22,26,28,29,31-36 have compared two or more different forms of folate supplementation.  The 248 
literature from this review did not find a substantial difference between the bioavailability of 249 
one or more forms. Only three studies 21,22,35 found a statistically significant difference between 250 
supplements and reporting 5-MTHF to be more bioavailable.  251 
 252 
However, these findings are subject to a number of limitations. The most significant was the 253 
short duration of the trials. Only tTwo studies 31,32 which tested RBC folate as an outcome 254 
measure only had a duration of 12 weeks. . These studies had a duration of 12 weeks making 255 
RBC folate is generally considered more an  appropriate choice for these for longer clinical 256 
trials 42. Red blood cell folate concentrations respond slowly to changes in folate intake due to 257 
the 120 day lifespan of red blood cells which accumulate folate only during erythropoiesis. 258 
This makes RBC folate a more reliable indicator of long-term folate status due to being less 259 
sensitive to fluctuations in dietary intake than plasma or serum folate 43. Therefore, RBC levels 260 
in a 12 week study may not produce meaningful results. A longer duration of 4 months is 261 
recommended to observe reliable changes in folate status as a result of the intervention. The 262 
other seven studies 19,26,28,29,33,34,36 which assessed two or more different forms of folate ranged 263 
from 3 days to 7 weeks and measured plasma or serum folate concentrations at multiple 264 
intervals. This is an appropriate and reliable outcome measure for the duration of those trials 265 
44.  However, it has been documented that shorter trial durations require a larger sample size 266 
to detect the same treatment effect 45. An important limitation to be noted is the effect dietary 267 
folate intake may have on the results. None of the studies included in this review monitored 268 
dietary folate intake in the days prior to or during the trial period with the exception of the 269 
animal studies which were fed controlled diets19-22. Due to the sensitivity of plasma and serum 270 
folate to fluctuations in dietary folate intake, monitoring dietary folate intake for the duration of 271 
the trials would give a clearer indication of the interventions effect and whether or not changes 272 
in dietary intake affected the results. The average number of participants from the studies 273 
reviewed was 15. This is another important limitation and may partially explain the lack of 274 
statistical significance observed in these trials.  275 
 276 
The review uncovered that only one study 26 has directly compared folic acid, folinic acid and 277 
5-MTHF. The study design was a three day quasi-experimental trial including seven male 278 
participants. There was no control group or placebo. The study measured 24 hour urinary 279 
folate levels and observed the excretion rates of each supplement.  The results of the study 280 
indicate relative differences in the excretion of folates but suggest that the intestinal absorption 281 
was similar among folate groups.  Slight differences were observed between treatment groups 282 
with folic acid appearing somewhat more bioavailable. This finding, while preliminary, 283 
suggests that differences in bioavailability exist for each supplement form.  As folic acid, folinic 284 
acid and 5-MTHF are the most common forms of folate available to health practitioners, 285 
assessing effectiveness is an important clinical question and larger clinical trials are needed 286 
to observe any true differences in outcome measures.  287 
 288 
Two trials 23,27 which tested varying dosages of folate had conflicting results. McGuire et al. 23 289 
found that incrementally increased dosages of folinic acid failed to increase circulating folate 290 
levels proportional to dosage.  In contrast, Truswell & Kounnavong 27 observed clear increases 291 
in serum folate levels in relation to each increased dosage of folic acid. There are several 292 
possible explanations for this result. For example, McGuire et al. 23 conducted a 4-way 293 
crossover trial where participants were given an individual dose and had blood taken at various 294 
intervals over 24 hours. Truswell & Kounnavong 27 had participants take one lower dose of 295 
folic acid every day for 3 weeks followed by a higher dose of folic acid for another 3 weeks. 296 
The differences in study design could be a possible explanation for the variations observed. 297 
These results could also suggests that folic acid and folinic acid have different bioavailability 298 
at different dosages and warrants further investigation.  299 
 300 
Two of the studies 29,31 included in this review considered individuals with MTHFR gene 301 
mutations. Both studies observed similar bioavailability between folate derivatives. Melse-302 
Boonstra et al. 31 assessed 180 participants in a 12 week, randomised, double-blind, placebo-303 
controlled trial. Two MTHFR polymorphisms were observed in the participants, 161 with the 304 
CC genotype and 19 with the CT genotype. The results concluded that the bioavailability of 305 
polyglutamyl folic acid relative to that of monoglutamyl folic acid did not differ significantly 306 
between genotypes. The second study found similar results. Litynski et al. 29 conducted a 307 
seven week quasi-experimental trial in 40 healthy adults. Of these, 20 were wild type and 20 308 
homozygous for the 677C→T polymorphism. The trial found that 5-MTHF displayed similar 309 
efficacy in reducing homocysteine as folic acid. Interestingly, a prolonged effect 6 months after 310 
ceasing treatment was observed with 5-MTHF in the homozygous participants. This raises 311 
important questions surrounding the processing and turnover time of folate in homozygous 312 
participants and more research is required to better understand the mechanisms involved.  313 
 314 
This review highlights the lack of studies evaluating the bioavailability of folate oral 315 
supplements. The discrepancies among the results for dose dependant studies warrants 316 
further experimental investigation. The data from the trials comparing different forms of folate 317 






The aim of this review was to assess the bioavailability of various forms of folate supplements 324 
in  healthy populations and animal models. This is an area of great importance as folate 325 
supplements are prescribed for a number of different health conditions and disease states. 326 
Choosing the most bioavailable form may improve treatment efficacy and patient results. This 327 
is the first review to assess the current literature on supplemental folate bioavailability in a 328 
healthy population. The review has uncovered some conflicting results and several 329 
methodological limitations. In particular, there is need for more research directly assessing the 330 
most common forms of folate supplements available to clinicians and the general public so 331 
that they can make informed choices. This will have implications for both clinical interventions 332 
and patient outcomes.  333 
 334 
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